Additionally, the CameL trial (ClinicalTrials.gov identifier NCT03134872), a multicentre randomized phase 3 trial, evaluated the combination of camrelizumab and pemetrexed-platinum chemotherapy (camrelizumab combination therapy) for previously untreated patients with advanced, non-squamous NSCLC without Alk or Egfr genomic aberrations. This evidence concerns the gene ALK and non-small cell lung carcinoma.